A 26-year-old woman presented with six months of abdominal discomfort. At laparotomy a 40 x 40 cm omental tumour invading the stomach and involving the spleen was found with multiple tumour nodules over all the peritoneal surface. Both ovaries were enlarged and a total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy and debulking procedure was undertaken. Significant residual disease remained. Histology showed an undifferentiated ovarian carcinoma. CA-125 was elevated at 225 U/ml (normal range 0-22). Immunostaining of the tumour showed CAM 5.2 positive, most marked in the larger cells, epithelial membrane antigen focal and faint positive, mixed cytokeratins (AE1) positive, beta human chorionic gonadotropin negative, alpha-fetoprotein focal and faint.
Answers QUESTION 1 Non-islet cell tumour hypoglycaemia (NICTH). In a patient with a metastatic carcinoma, not receiving insulin or sulphonylurea therapy, an insulinoma is possible but other causes such as liver failure, adrenal insufficiency and NICTH are more likely.' In this patient, undetectable insulin and C-peptide during hypoglycaemia with normal adrenal and liver function tests suggested that she had NICTH. This was confirmed by the IGF assays. Other tumours associated with NICTH are shown in the box. QUESTION 2 Therapeutic somatotropin (growth hormone) increases IGF-I and, therefore, IGF-BP3 concentration so reducing the bioavailability of 'big' IGF-II'. Prednisolone decreases tumour secretion of pre-IGF-II forms such as 'big' IGF-II and increases binding to acid-labile subunit, so further reducing its bioavailability.' The combination of these therapies is therefore beneficial, and facilitated the management of this patient at home.
Discussion
In any patient with significant hypoglycaemia, and no evidence of adrenal or hepatic disease, the initial question is whether there is insulin and C-peptide present. If insulin is high but no C-peptide is found, exogenous administration of insulin should be considered. With high insulin and C-peptide this may be from an insulinoma or pharmacological agents such as sulphonylureas, or less commonly sulphonamides in patients with renal disease. If insulin levels are low, such as in our patient, then what is reducing the glucose? IGFs can do this and checking IGF-I, IGF-II and binding proteins will help to decide the cause.
NICTH usually occurs with large mesenchymal or epithelial tumours weighing over 1 kg and measuring more than 5 cm in diameter2; some potential causes are shown in box 1. This phenomenon has not, to our knowledge, previously been reported with an ovarian carcinoma. These tumours may produce 'big' IGF- and an acid-labile subunit.' 2 In this form IGF is unable to leave the circulation.3 'Big' IGF-II can bind to IGF-BP3 but its affinity for the acid-labile subunit is reduced. Complexed with IGF-BP3 alone it can leave the circulation, so increasing its bioavailability.1 2 'Big' IGF-II suppresses somatotropin production, so reducing both IGF-I and IGF-BP3 production, again increasing its bioavailability.'
Final diagnosis
Non-islet cell tumour hypoglycaemia.
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